<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font19 { font-size : 19; } .font21 { font-size : 21; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font29 { font-size : 29; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font29">the </span>
   <span class="font21">with </span>
   <span class="font19">patients </span>
   <span class="font17">for </span>
   <span class="font16">[]. </span>
   <span class="font15">COVID- </span>
   <span class="font13">severe </span>
   <span class="font13">that </span>
   <span class="font12">treatment </span>
   <span class="font12">may </span>
   <span class="font12">are </span>
   <span class="font12">respiratory </span>
   <span class="font12">was </span>
   <span class="font12">study </span>
   <span class="font12">days </span>
   <span class="font12">not </span>
   <span class="font12">The </span>
   <span class="font12">use </span>
   <span class="font12">therapy </span>
   <span class="font11">clinical </span>
   <span class="font11">from </span>
   <span class="font11">who </span>
   <span class="font11">immune </span>
   <span class="font11">acute </span>
   <span class="font11">effects </span>
   <span class="font11">received </span>
   <span class="font11">viral </span>
   <span class="font11">have </span>
   <span class="font11">plasma </span>
   <span class="font11">infection </span>
   <span class="font11">{background </span>
   <span class="font11">cytokine </span>
   <span class="font11">disease </span>
   <span class="font11">role </span>
   <span class="font11">associated </span>
   <span class="font11">hydroxychloroquine </span>
   <span class="font11">trial </span>
   <span class="font11">were </span>
   <span class="font11">[], </span>
   <span class="font11">coronavirus </span>
   <span class="font11">syndrome </span>
   <span class="font11">also </span>
   <span class="font11">convalescent </span>
   <span class="font11">Accessed </span>
   <span class="font11">anti-inflammatory </span>
   <span class="font11">day </span>
   <span class="font11">potential </span>
   <span class="font11">randomized </span>
   <span class="font11">these </span>
   <span class="font11">this </span>
   <span class="font11">which </span>
   <span class="font11">GM-CSF </span>
   <span class="font11">been </span>
   <span class="font11">has </span>
   <span class="font11">inflammatory </span>
   <span class="font11">margin </span>
   <span class="font11">reported </span>
   <span class="font11">can </span>
   <span class="font11">receptor </span>
   <span class="font11">such </span>
   <span class="font11">{border-style </span>
   <span class="font10">IL- </span>
   <span class="font10">IVIG </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">dose </span>
   <span class="font10">ill </span>
   <span class="font10">increased </span>
   <span class="font10">response </span>
   <span class="font10">safety </span>
   <span class="font10">immunomodulatory </span>
   <span class="font10">lung </span>
   <span class="font10">px;} </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">COVID-, </span>
   <span class="font10">combination </span>
   <span class="font10">other </span>
   <span class="font10">risk </span>
   <span class="font10">should </span>
   <span class="font10">antiviral </span>
   <span class="font10">cells </span>
   <span class="font10">efficacy </span>
   <span class="font10">factor </span>
   <span class="font10">vs. </span>
   <span class="font10">ARDS </span>
   <span class="font10">SARS-CoV- </span>
   <span class="font10">daily </span>
   <span class="font10">effect </span>
   <span class="font10">human </span>
   <span class="font10">management </span>
   <span class="font10">mortality </span>
   <span class="font10">phase </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">anakinra </span>
   <span class="font10">critically </span>
   <span class="font10">evaluating </span>
   <span class="font10">mechanical </span>
   <span class="font10">pneumonia </span>
   <span class="font10">proinflammatory </span>
   <span class="font10">storm </span>
   <span class="font10">system </span>
   <span class="font10">trials </span>
   <span class="font10">after </span>
   <span class="font10">any </span>
   <span class="font10">bid </span>
   <span class="font10">controlled </span>
   <span class="font10">days; </span>
   <span class="font10">intravenous </span>
   <span class="font10">pulmonary </span>
   <span class="font10">two </span>
   <span class="font10">within </span>
   <span class="font10">(e.g. </span>
   <span class="font10">-day </span>
   <span class="font10">COVID-. </span>
   <span class="font10">JAK </span>
   <span class="font10">Patients </span>
   <span class="font10">Use </span>
   <span class="font10">against </span>
   <span class="font10">although </span>
   <span class="font10">colchicine </span>
   <span class="font10">cytokines </span>
   <span class="font10">drugs </span>
   <span class="font10">effective </span>
   <span class="font10">hospitalized </span>
   <span class="font10">immunity </span>
   <span class="font10">infections, </span>
   <span class="font10">inflammation </span>
   <span class="font10">levels </span>
   <span class="font10">more </span>
   <span class="font10">patients. </span>
   <span class="font10">statins </span>
   <span class="font10">symptoms </span>
   <span class="font10">ventilation </span>
   <span class="font10">virus </span>
   <span class="font10">â€"Â </span>
   <span class="font10">However, </span>
   <span class="font10">May </span>
   <span class="font10">adverse </span>
   <span class="font10">al. </span>
   <span class="font10">chloroquine </span>
   <span class="font10">colony-stimulating </span>
   <span class="font10">epithelial </span>
   <span class="font10">high </span>
   <span class="font10">including </span>
   <span class="font10">increase </span>
   <span class="font10">infections </span>
   <span class="font10">its </span>
   <span class="font10">primary </span>
   <span class="font10">retrospective </span>
   <span class="font10">showed </span>
   <span class="font10">shown </span>
   <span class="font10">significant </span>
   <span class="font10">studies </span>
   <span class="font10">systemic </span>
   <span class="font10">those </span>
   <span class="font10">CYPA </span>
   <span class="font10">adaptive </span>
   <span class="font10">arm </span>
   <span class="font10">azithromycin </span>
   <span class="font10">benefit </span>
   <span class="font10">caution </span>
   <span class="font10">compared </span>
   <span class="font10">death </span>
   <span class="font10">described </span>
   <span class="font10">events </span>
   <span class="font10">inhibitors </span>
   <span class="font10">innate </span>
   <span class="font10">methylprednisolone </span>
   <span class="font10">multicenter, </span>
   <span class="font10">only </span>
   <span class="font10">patients, </span>
   <span class="font10">receiving </span>
   <span class="font10">renal </span>
   <span class="font10">single </span>
   <span class="font10">survival </span>
   <span class="font10">their </span>
   <span class="font10">time </span>
   <span class="font10">using </span>
   <span class="font10">will </span>
   <span class="font10">(NCT). </span>
   <span class="font10">ACE </span>
   <span class="font10">COVID-: </span>
   <span class="font10">Infect </span>
   <span class="font10">SARS </span>
   <span class="font10">There </span>
   <span class="font10">adults </span>
   <span class="font10">cohort </span>
   <span class="font10">currently </span>
   <span class="font10">days, </span>
   <span class="font10">decreased </span>
   <span class="font10">difference </span>
   <span class="font10">effects, </span>
   <span class="font10">important </span>
   <span class="font10">improvement </span>
   <span class="font10">inhibit </span>
   <span class="font10">injury </span>
   <span class="font10">possible </span>
   <span class="font10">randomized, </span>
   <span class="font10">severely </span>
   <span class="font10">therapeutic </span>
   <span class="font10">(i.e. </span>
   <span class="font10">ACEi </span>
   <span class="font10">Care </span>
   <span class="font10">Not </span>
   <span class="font10">adult </span>
   <span class="font10">agent </span>
   <span class="font10">agents </span>
   <span class="font10">al.A </span>
   <span class="font10">baricitinib </span>
   <span class="font10">being </span>
   <span class="font10">beneficial </span>
   <span class="font10">between </span>
   <span class="font10">both </span>
   <span class="font10">care </span>
   <span class="font10">component </span>
   <span class="font10">decrease </span>
   <span class="font10">dexamethasone </span>
   <span class="font10">drug </span>
   <span class="font10">due </span>
   <span class="font10">duration </span>
   <span class="font10">elderly </span>
   <span class="font10">enzyme </span>
   <span class="font10">grid.. </span>
   <span class="font10">improved </span>
   <span class="font10">included </span>
   <span class="font10">indicated </span>
   <span class="font10">likely </span>
   <span class="font10">moderate </span>
   <span class="font10">necrosis </span>
   <span class="font10">novel </span>
   <span class="font10">once </span>
   <span class="font10">one </span>
   <span class="font10">open-label, </span>
   <span class="font10">patient </span>
   <span class="font10">play </span>
   <span class="font10">positive </span>
   <span class="font10">px; </span>
   <span class="font10">reduced </span>
   <span class="font10">reduction </span>
   <span class="font10">review </span>
   <span class="font10">signaling </span>
   <span class="font10">site </span>
   <span class="font10">three </span>
   <span class="font10">tract </span>
   <span class="font10">used </span>
   <span class="font10">{font-family </span>
   <span class="font10">.â€"., </span>
   <span class="font10">Additionally, </span>
   <span class="font10">Ang </span>
   <span class="font10">Apr </span>
   <span class="font10">Clin </span>
   <span class="font10">Clinical </span>
   <span class="font10">Health </span>
   <span class="font10">III </span>
   <span class="font10">Janus </span>
   <span class="font10">Medicine, </span>
   <span class="font10">National </span>
   <span class="font10">Respir </span>
   <span class="font10">SARS-CoV </span>
   <span class="font10">This </span>
   <span class="font10">Thus, </span>
   <span class="font10">[â€"]. </span>
   <span class="font10">abdominal </span>
   <span class="font10">adjunctive </span>
   <span class="font10">all </span>
   <span class="font10">antagonist </span>
   <span class="font10">anti-TNFÎ± </span>
   <span class="font10">antibodies </span>
   <span class="font10">antibody </span>
   <span class="font10">cardiac </span>
   <span class="font10">distress </span>
   <span class="font10">doses </span>
   <span class="font10">during </span>
   <span class="font10">dysfunction </span>
   <span class="font10">early </span>
   <span class="font10">edema, </span>
   <span class="font10">evidence </span>
   <span class="font10">failure </span>
   <span class="font10">following </span>
   <span class="font10">font-size </span>
   <span class="font10">form </span>
   <span class="font10">granulocyteâ€"macrophage </span>
   <span class="font10">had </span>
   <span class="font10">high-dose </span>
   <span class="font10">higher </span>
   <span class="font10">host </span>
   <span class="font10">hypersensitivity </span>
   <span class="font10">illness </span>
   <span class="font10">influenza </span>
   <span class="font10">inhibitor </span>
   <span class="font10">intensive </span>
   <span class="font10">investigated </span>
   <span class="font10">myocardial </span>
   <span class="font10">observed </span>
   <span class="font10">open-label </span>
   <span class="font10">prevent </span>
   <span class="font10">protein </span>
   <span class="font10">provide </span>
   <span class="font10">recombinant </span>
   <span class="font10">reduce </span>
   <span class="font10">result </span>
   <span class="font10">results </span>
   <span class="font10">statin </span>
   <span class="font10">subcutaneous </span>
   <span class="font10">than </span>
   <span class="font10">transfusion </span>
   <span class="font10">(.%) </span>
   <span class="font10">(NCT) </span>
   <span class="font10">ARB </span>
   <span class="font10">Anti-cytokine, </span>
   <span class="font10">CRS </span>
   <span class="font10">Chinese </span>
   <span class="font10">Hypersensitivity </span>
   <span class="font10">Rev </span>
   <span class="font10">TNFÎ± </span>
   <span class="font10">Treatment </span>
   <span class="font10">University </span>
   <span class="font10">While </span>
   <span class="font10">activation </span>
   <span class="font10">allergic </span>
   <span class="font10">angiotensin </span>
   <span class="font10">cardiovascular </span>
   <span class="font10">caused </span>
   <span class="font10">demonstrated </span>
   <span class="font10">did </span>
   <span class="font10">double-blind, </span>
   <span class="font10">double; </span>
   <span class="font10">evaluated </span>
   <span class="font10">headache, </span>
   <span class="font10">immunosuppressive </span>
   <span class="font10">infection. </span>
   <span class="font10">infection: </span>
   <span class="font10">inhibiting </span>
   <span class="font10">known </span>
   <span class="font10">less </span>
   <span class="font10">low-dose </span>
   <span class="font10">macrophage </span>
   <span class="font10">might </span>
   <span class="font10">nausea, </span>
   <span class="font10">need </span>
   <span class="font10">new </span>
   <span class="font10">observational </span>
   <span class="font10">outcome </span>
   <span class="font10">pain, </span>
   <span class="font10">pâ€‰=â€‰.). </span>
   <span class="font10">rates </span>
   <span class="font10">receive </span>
   <span class="font10">regimen </span>
   <span class="font10">remdesivir </span>
   <span class="font10">required </span>
   <span class="font10">requiring </span>
   <span class="font10">secondary </span>
   <span class="font10">significantly </span>
   <span class="font10">stages </span>
   <span class="font10">standard </span>
   <span class="font10">statistically </span>
   <span class="font10">suggest </span>
   <span class="font10">symptoms, </span>
   <span class="font10">then </span>
   <span class="font10">there </span>
   <span class="font10">through </span>
   <span class="font10">twice </span>
   <span class="font10">under </span>
   <span class="font10">underway </span>
   <span class="font10">when </span>
   <span class="font10">(%) </span>
   <span class="font10">(HR </span>
   <span class="font10">(NCT, </span>
   <span class="font10">.â€".; </span>
   <span class="font10">Allergy </span>
   <span class="font10">Anti-inflammatory </span>
   <span class="font10">Antimicrob </span>
   <span class="font10">East </span>
   <span class="font10">Engl </span>
   <span class="font10">FDA-approved </span>
   <span class="font10">IL-, </span>
   <span class="font10">Investig./JCI </span>
   <span class="font10">Middle </span>
   <span class="font10">NCT, </span>
   <span class="font10">School </span>
   <span class="font10">TNF </span>
   <span class="font10">action </span>
   <span class="font10">activity </span>
   <span class="font10">advanced </span>
   <span class="font10">agents, </span>
   <span class="font10">alone </span>
   <span class="font10">another </span>
   <span class="font10">autoimmune </span>
   <span class="font10">benefits </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">but </span>
   <span class="font10">cell </span>
   <span class="font10">cells, </span>
   <span class="font10">complications </span>
   <span class="font10">confer </span>
   <span class="font10">confirmed </span>
   <span class="font10">could </span>
   <span class="font10">critical </span>
   <span class="font10">current </span>
   <span class="font10">daily, </span>
   <span class="font10">data </span>
   <span class="font10">different </span>
   <span class="font10">direct </span>
   <span class="font10">disease, </span>
   <span class="font10">elevated </span>
   <span class="font10">every </span>
   <span class="font10">factor, </span>
   <span class="font10">failure, </span>
   <span class="font10">fever, </span>
   <span class="font10">followed </span>
   <span class="font10">hepatic </span>
   <span class="font10">history </span>
   <span class="font10">hospital </span>
   <span class="font10">however, </span>
   <span class="font10">impairment </span>
   <span class="font10">key </span>
   <span class="font10">low </span>
   <span class="font10">lower </span>
   <span class="font10">mechanisms </span>
   <span class="font10">modulators </span>
   <span class="font10">most </span>
   <span class="font10">multiorgan </span>
   <span class="font10">nebulized </span>
   <span class="font10">negative </span>
   <span class="font10">onset </span>
   <span class="font10">outcomes </span>
   <span class="font10">oxygen </span>
   <span class="font10">pathway </span>
   <span class="font10">plasma, </span>
   <span class="font10">population </span>
   <span class="font10">potentially </span>
   <span class="font10">production </span>
   <span class="font10">protective </span>
   <span class="font10">pâ€‰ </span>
   <span class="font10">pâ€‰=â€‰.) </span>
   <span class="font10">replication </span>
   <span class="font10">responses </span>
   <span class="font10">route </span>
   <span class="font10">ruxolitinib </span>
   <span class="font10">sarilumab </span>
   <span class="font10">sepsis </span>
   <span class="font10">serum </span>
   <span class="font10">several </span>
   <span class="font10">short-term </span>
   <span class="font10">solid; </span>
   <span class="font10">stage </span>
   <span class="font10">suggesting </span>
   <span class="font10">systematic </span>
   <span class="font10">taking </span>
   <span class="font10">therapy, </span>
   <span class="font10">transfusion, </span>
   <span class="font10">tumor </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(.% </span>
   <span class="font10">.â€".) </span>
   <span class="font10">ALT, </span>
   <span class="font10">Although </span>
   <span class="font10">Another </span>
   <span class="font10">Avoid </span>
   <span class="font10">COVID-J </span>
   <span class="font10">CRP </span>
   <span class="font10">California, </span>
   <span class="font10">Colchicine </span>
   <span class="font10">Crit </span>
   <span class="font10">Department </span>
   <span class="font10">Infect./j.jinf... </span>
   <span class="font10">International </span>
   <span class="font10">JAK-STAT </span>
   <span class="font10">Known </span>
   <span class="font10">Mar </span>
   <span class="font10">Med </span>
   <span class="font10">Med./NEJMoa </span>
   <span class="font10">MyD </span>
   <span class="font10">NCT). </span>
   <span class="font10">New </span>
   <span class="font10">None </span>
   <span class="font10">Other </span>
   <span class="font10">PGD </span>
   <span class="font10">Sci </span>
   <span class="font10">Since </span>
   <span class="font10">Society </span>
   <span class="font10">Specific </span>
   <span class="font10">These </span>
   <span class="font10">Tocilizumab </span>
   <span class="font10">[package </span>
   <span class="font10">[published </span>
   <span class="font10">addition, </span>
   <span class="font10">admitted </span>
   <span class="font10">al.The </span>
   <span class="font10">among </span>
   <span class="font10">analysis </span>
   <span class="font10">appears </span>
   <span class="font10">azithromycin, </span>
   <span class="font10">binding </span>
   <span class="font10">bold </span>
   <span class="font10">case </span>
   <span class="font10">cause </span>
   <span class="font10">chest </span>
   <span class="font10">chronic </span>
   <span class="font10">clearance </span>
   <span class="font10">commenced </span>
   <span class="font10">concern </span>
   <span class="font10">continued </span>
   <span class="font10">correction </span>
   <span class="font10">corticosteroid </span>
   <span class="font10">courier; </span>
   <span class="font10">covid-N </span>
   <span class="font10">days) </span>
   <span class="font10">days. </span>
   <span class="font10">dosing </span>
   <span class="font10">dual </span>
   <span class="font10">either </span>
   <span class="font10">em; </span>
   <span class="font10">endpoint </span>
   <span class="font10">factors </span>
   <span class="font10">findings </span>
   <span class="font10">first </span>
   <span class="font10">formulation </span>
   <span class="font10">formulation, </span>
   <span class="font10">four </span>
   <span class="font10">functions </span>
   <span class="font10">hypertension, </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">immunoglobulin, </span>
   <span class="font10">immunomodulators </span>
   <span class="font10">immunopathology </span>
   <span class="font10">impact </span>
   <span class="font10">improve </span>
   <span class="font10">indication </span>
   <span class="font10">inflammation, </span>
   <span class="font10">infusion </span>
   <span class="font10">inhibitors, </span>
   <span class="font10">injection </span>
   <span class="font10">insert]. </span>
   <span class="font10">interferon </span>
   <span class="font10">invasive </span>
   <span class="font10">investigation </span>
   <span class="font10">large </span>
   <span class="font10">lead </span>
   <span class="font10">lymphopenia </span>
   <span class="font10">mainly </span>
   <span class="font10">mg/kg </span>
   <span class="font10">monoclonal </span>
   <span class="font10">monocytes </span>
   <span class="font10">neutralizing </span>
   <span class="font10">newly </span>
   <span class="font10">number </span>
   <span class="font10">option </span>
   <span class="font10">particularly </span>
   <span class="font10">pilot </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">plus </span>
   <span class="font10">pneumonia: </span>
   <span class="font10">potent </span>
   <span class="font10">pregnancy </span>
   <span class="font10">preventing </span>
   <span class="font10">prevention </span>
   <span class="font10">properties </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">proposed </span>
   <span class="font10">pt;} </span>
   <span class="font10">published </span>
   <span class="font10">rash, </span>
   <span class="font10">rate </span>
   <span class="font10">reactions, </span>
   <span class="font10">recommended </span>
   <span class="font10">reduces </span>
   <span class="font10">relevant </span>
   <span class="font10">retrospective, </span>
   <span class="font10">revealed </span>
   <span class="font10">search </span>
   <span class="font10">severity </span>
   <span class="font10">shorter </span>
   <span class="font10">six </span>
   <span class="font10">specific </span>
   <span class="font10">strategies </span>
   <span class="font10">support </span>
   <span class="font10">syndrome: </span>
   <span class="font10">they </span>
   <span class="font10">transplant </span>
   <span class="font10">treating </span>
   <span class="font10">unit </span>
   <span class="font10">various </span>
   <span class="font10">via </span>
   <span class="font10">well-tolerated </span>
   <span class="font10">whom </span>
  </p>
 </body>
</html>
